Warning letter
ProRx LLC: warning letter of Apr 7, 2026
FDA warning letter 723704 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 723704 |
|---|---|
| Company | ProRx LLC |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Apr 7, 2026 |
| Posted date | May 12, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 200.10(b), 201.115, 210.1(b), 211.22(c), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.113(b), 211.192, 310.305(c)(2), 310.305(b) |
| Inspection city | Exton |
| Inspection ZIP | 19341 |
| Inspection start date | Sep 9, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: